Factor Bioscience Announces U.S. Department of Defense Grant to Develop Gene-Edited Cell Therapies
January 9, 2024
-Leverages Factor’s extensively patented mRNA, cell-reprogramming, and gene-editing technologies -Cell therapy candidates will initially be developed for the treatment of Duchenne muscular dystrophy (“DMD”) -Other planned applications include infectious, inflammatory, and autoimmune indications CAMBRIDGE, Mass., January 9, 2024 /PRNewswire/ — Factor Bioscience Inc. (“Factor”), a Cambridge, Massachusetts-based biotechnology company developing advanced mRNA and cell-engineering technologies, announced […]